Modra

Phase I results with ModraDoc006/r published in the European Journal of Cancer

14 october 2017

Researchers from the Netherlands Cancer Institute have published results from a Phase I study with oral docetaxel in the European Journal of Cancer, in a paper titled, ‘A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir’.

 

Read the publication in the European Journal of Cancer

 

This is the first publication of safety, tolerability and initial clinical activity data for ModraDoc006/r in patients with metastatic solid tumors.




News

Phase I results with ModraDoc006/r published in the European Journal of Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more

Events

Meet us at one of the following events:      
Read more